Tandem Diabetes Care Inc (TNDM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tandem Diabetes Care Inc (TNDM) has a cash flow conversion efficiency ratio of 0.083x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($11.05 Million) by net assets ($132.40 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Tandem Diabetes Care Inc to measure how many days the company can operate on defensive assets alone.
Tandem Diabetes Care Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Tandem Diabetes Care Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Tandem Diabetes Care Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tandem Diabetes Care Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beijing E Hualu Info Tech
SHE:300212
|
-0.019x |
|
Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund
NYSE:PTA
|
N/A |
|
China Union Holdings Ltd
SHE:000036
|
-0.005x |
|
Universal Insurance Holdings Inc
NYSE:UVE
|
0.265x |
|
Ningbo Changhong Polymer Scientific & Technical Inc
SHG:605008
|
-0.082x |
|
Bellring Brands LLC
NYSE:BRBR
|
0.022x |
|
Elco Ltd
TA:ELCO
|
-0.042x |
|
Corbion N.V.
F:CSU
|
0.038x |
Annual Cash Flow Conversion Efficiency for Tandem Diabetes Care Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Tandem Diabetes Care Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see Tandem Diabetes Care Inc (TNDM) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $155.17 Million | $-9.72 Million | -0.063x | -168.04% |
| 2024-12-31 | $263.10 Million | $24.23 Million | 0.092x | +190.78% |
| 2023-12-31 | $313.63 Million | $-31.81 Million | -0.101x | -188.42% |
| 2022-12-31 | $439.95 Million | $50.46 Million | 0.115x | -55.39% |
| 2021-12-31 | $433.11 Million | $111.36 Million | 0.257x | +281.78% |
| 2020-12-31 | $366.31 Million | $24.67 Million | 0.067x | -68.67% |
| 2019-12-31 | $194.98 Million | $41.91 Million | 0.215x | +439.16% |
| 2018-12-31 | $131.28 Million | $-8.32 Million | -0.063x | -102.79% |
| 2017-12-31 | $-29.15 Million | $-66.14 Million | 2.269x | -78.02% |
| 2016-12-31 | $-5.93 Million | $-61.17 Million | 10.321x | +1214.73% |
| 2015-12-31 | $63.47 Million | $-58.76 Million | -0.926x | +17.68% |
| 2014-12-31 | $54.57 Million | $-61.38 Million | -1.125x | -172.10% |
| 2013-12-31 | $115.54 Million | $-47.76 Million | -0.413x | -230.97% |
| 2012-12-31 | $-106.05 Million | $-33.47 Million | 0.316x | +4.43% |
| 2011-12-31 | $-71.29 Million | $-21.55 Million | 0.302x | -- |
About Tandem Diabetes Care Inc
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and … Read more